

Metals in Medicine

Second Edition

James C. Dabrowiak

Department of Chemistry, Syracuse University, New York, USA

WILEY

Contents

Feature Boxes	xv
Preface to the Second Edition	xvii
Preface to the First Edition	xix
Acknowledgments	xxi
About the Companion Website	xxiii
1 Inorganic Chemistry Basics	1
1.1 Introduction	1
1.2 Crystal Field Theory	1
1.2.1 Octahedral Crystal Field	2
1.2.2 Other Crystal Fields	6
1.2.3 Factors Affecting the Crystal Field Splitting Parameter, Δ	8
1.2.3.1 Spectrochemical Series	8
1.2.3.2 Principal Quantum Number, n	9
1.2.3.3 Metal Ion Oxidation State	9
1.2.4 High- and Low-Spin Complexes	10
1.3 Molecular Orbital Theory	12
1.3.1 MO Diagram of Molecular Hydrogen	13
1.3.2 MO Diagram for $[\text{Co}(\text{NH}_3)_6]^{3+}$	15
1.4 Absorption Spectra of Metal Complexes	22
1.4.1 Band Intensity/Selection Rules	25
1.4.2 Absorption Spectra of Multi-Electron Systems	27
1.5 Magnetic Properties of Metal Complexes	33
1.6 Structure and Reactivity of Metal Complexes	35
1.6.1 Forward and Reverse Rates and Equilibrium	35
1.6.2 Water Exchange Rates for Metal Ions	36
1.6.3 Transition State Theory, the Kinetic Rate Constant and Equilibrium	38
1.6.4 <i>Trans</i> Effect and Substitution Reactions	40
1.6.5 Stability of Metal Complexes	44
1.6.6 Chelate Effect	46
1.6.7 Macrocyclic Effect	50
1.6.8 Hard–Soft Acids–Bases	52
1.7 Summary	53
Discussion Questions	55
Problems	55
References	57
Further Reading	57

2	Metallo-Drugs and Their Action	59
2.1	Introduction	59
2.2	Proteins as Targets for Metallo-Drugs	59
2.2.1	Protein Structure	60
2.2.2	Metal-Binding Sites on Proteins	62
2.3	DNA as a Target for Metallo-Drugs	71
2.3.1	Structure of DNA and RNA	71
2.3.2	Metal-Binding Sites on DNA	74
2.4	Reaction of Metal Complexes in the Biological Milieu	76
2.4.1	Reactions with Chloride	76
2.4.2	Reactions with Phosphate	77
2.4.3	Reactions with Carbonate	77
2.5	Evaluating the Pharmacological Effects of Agents	79
2.5.1	Measuring the Cytotoxicity of a Drug	79
2.5.2	Measuring Drug Uptake	81
2.5.3	Animal Studies	81
2.6	From Discovery to the Clinic	82
2.6.1	Preclinical Phase of the Drug-Approval Process	82
2.6.2	Investigational New Drug (IND) Application	83
2.6.3	Phase I Clinical Trials	83
2.6.4	Phase II Clinical Trials	83
2.6.5	Phase III Clinical Trials	84
2.6.6	New Drug Application	84
2.6.7	Post-Marketing	84
2.6.8	Cost of Research and Development	84
2.7	Summary	85
	Discussion Questions	86
	Problems	87
	References	88
	Further Reading	89
3	Platinum Drugs for Treating Cancer	91
3.1	Introduction	91
3.2	Cisplatin	91
3.2.1	Physical and Chemical Properties of Cisplatin	94
3.2.2	Formulation, Administration, Pharmacokinetics and Adverse Reactions of Cisplatin	96
3.2.3	Reaction of Cisplatin in Blood	97
3.2.4	Uptake (Influx) of Cisplatin by Cells	97
3.2.5	Removal (Efflux) of Cisplatin from Cells: Resistance	99
3.2.6	DNA as a Target for Cisplatin	100
3.2.7	Non-DNA Targets for Cisplatin	109
3.2.7.1	Membrane Proteins	110
3.2.7.2	Zinc Finger Proteins	110
3.2.7.3	Tubulin	111
3.2.7.4	Thioredoxin Reductase	112
3.2.7.5	Stress Response Proteins	112
3.2.7.6	RNA	114

3.3	Carboplatin	115
3.3.1	Synthesis and Properties of Carboplatin	115
3.3.2	Formulation, Administration, Pharmacokinetics and Adverse Reactions of Carboplatin	118
3.3.3	Carboplatin Activation: Breaking the Ring	118
3.3.4	Reaction of Carboplatin with Blood Proteins	121
3.3.5	Cytotoxicity and Uptake of Carboplatin	121
3.3.6	Interaction of Carboplatin with Cellular Targets	123
3.4	Oxaliplatin	126
3.4.1	Synthesis and Properties of Oxaliplatin	126
3.4.2	Formulation, Administration, Pharmacokinetics and Adverse Reactions of Oxaliplatin	128
3.4.3	Reaction of Oxaliplatin in Blood	128
3.4.4	Uptake of Oxaliplatin by Cells	130
3.4.5	Interaction of Oxaliplatin with Cellular Targets	130
3.5	Regionally Used Platinum Drugs	133
3.5.1	Nedaplatin	133
3.5.2	Lobaplatin	134
3.5.3	Heptaplatin	135
3.6	Platinum Agents in Preclinical Development	135
3.6.1	Sterically Hindered Agents	135
3.6.2	Compounds with the <i>Trans</i> Geometry	136
3.6.3	Biologically Active ‘Cargo’ Molecules	137
3.6.4	Monofunctional Platinum Complexes	137
3.6.5	Multinuclear Platinum Compounds	137
3.6.6	Platinum(IV) Prodrugs	138
3.6.7	Platinum Compounds that do not Attack DNA	140
3.6.8	Lipoplatin	140
3.7	Summary	141
	Discussion Questions	143
	Problems	144
	References	146
4	Anticancer Agents Beyond Cisplatin	157
4.1	Introduction	157
4.2	Ruthenium Anticancer Agents	157
4.2.1	Chemistry of Ruthenium in the Biological Milieu	157
4.2.2	Structure, Synthesis and Properties of Ruthenium Antitumor Agents	158
4.2.3	Synthesis and Biological Properties of NAMI-A	159
4.2.4	Control of Tumor Growth by NAMI-A	163
4.2.5	Clinical Trials with NAMI-A	163
4.2.6	Interaction of NAMI-A with Potential Biological Targets	163
4.2.7	Synthesis and Reactivity of KP1019	165
4.2.8	Anticancer and Biological Activity of KP1019	165
4.2.9	Interaction of KP1019 with Biological Molecules	166
4.2.10	Synthesis and Properties of Ruthenium Arene (Half-Sandwich) Compounds	168
4.2.11	Biological Activity of the Arene Complexes	169

4.3	Gold Anticancer Agents	173
4.3.1	Structures, Synthesis and Properties of Gold Anticancer Agents	173
4.3.2	Cellular Targets of the Gold Anticancer Agents	176
4.4	Titanium Compounds for Treating Cancer	181
4.4.1	Structure, Synthesis and Properties of Titanocene Dichloride	182
4.4.2	Interaction of Titanocene Dichloride with Potential Biological Targets	183
4.4.3	Structure, Synthesis, and Properties of Budotitane	183
4.4.4	Antitumor Activity and Clinical Trials with Budotitane	184
4.4.5	Biological Interactions of Budotitane	184
4.4.6	Titanium Anticancer Drugs in Development	184
4.5	Gallium for Treating Cancer	187
4.5.1	Chemistry of Gallium in Biological Media	187
4.5.2	Structures, Synthesis and Properties of Gallium Anticancer Agents	188
4.5.3	Uptake, Cytotoxicity and Reactivity of Gallium Agents in the Biological System	189
4.5.4	Gallium Anticancer Agents in Development	193
4.6	Other Anticancer Active Metal Complexes	194
4.6.1	Palladium	194
4.6.2	Osmium	196
4.6.3	Rhodium and Iridium	199
4.7	Summary	201
	Discussion Questions	203
	Problems	204
	References	206
	Further Reading	216
5	Responsive Metal Complexes	217
5.1	Introduction	217
5.2	Prodrug Activation by Redox	217
5.2.1	Platinum	217
5.2.2	Cobalt	220
5.2.3	Copper	222
5.2.4	Iron	222
5.3	Prodrug Activation by pH	225
5.4	Prodrug Activation by Enzymes	227
5.5	Prodrug Activation by Light	229
5.5.1	Photo-Release of a Cytotoxic Metal Complex	229
5.5.2	Photo-Release of Bound Drug Molecules	230
5.5.3	Photo-Release of Cell-Signaling Molecules	231
5.6	Photodynamic Therapy	233
5.6.1	Porphyrins	233
5.6.2	Phthalocyanines	236
5.6.3	Texaphyrins	237
5.6.4	Bacteriopheophorbides	237
5.7	Summary	237
	Discussion Questions	238
	Problems	239
	References	240
	Further Reading	244

6	Metal Complexes for Treating Arthritis and Diabetes	245
6.1	Introduction	245
6.2	Chemistry of Gold in Biological Media	245
6.3	Gold Compounds for Treating Arthritis	247
6.3.1	Structures, Synthesis and Properties of Gold Anti-Arthritic Drugs	247
6.3.2	Formulation, Administration and Pharmacokinetics of Gold Anti-Arthritic Drugs	250
6.3.3	Reactions of Gold Drugs in Biological Media	250
6.3.4	Interaction of Gold Drugs with Cellular Targets	254
6.3.4.1	Glutathione Reductase	258
6.3.4.2	Zinc Finger Proteins	258
6.3.4.3	Protein Tyrosine Phosphatases	262
6.4	Vanadium Compounds for Treating Diabetes	263
6.4.1	Diabetes Mellitus	264
6.4.2	Bis(ethylmaltolato)oxovanadium(IV) and Bis(maltolate)oxovanadium(IV)	265
6.4.3	Other Vanadium Complexes with Insulin-Mimetic Properties	273
6.5	Summary	276
	Discussion Questions	277
	Problems	278
	References	279
	Further Reading	283
7	Metal Complexes for Killing Parasites, Bacteria and Viruses	285
7.1	Introduction	285
7.2	Malaria	285
7.2.1	Antimalarial Drugs	286
7.2.2	Metallo-Antimalarial Agents	291
7.3	Leishmaniasis	293
7.3.1	Antileishmanial Drugs	294
7.3.2	Antileishmanial Drugs in Development	296
7.4	American Trypanosomiasis (Chagas Disease)	298
7.4.1	Trypanocidal Drugs	298
7.4.2	Metallo-Trypanocidal Drugs in Development	299
7.5	Human African Trypanosomiasis	301
7.6	Tuberculosis	301
7.6.1	The Antituberculosis Drug, Isoniazid	303
7.6.2	Metallo-Antituberculosis Drugs in Development	303
7.7	Peptic Ulcer Disease	306
7.7.1	Bismuth Anti-Ulcer Drugs	307
7.7.2	Metallo-Anti-Ulcer Drugs in Development	309
7.7.3	Metallo-Drugs for Treating Minor Gastrointestinal Disorders	310
7.8	Syphilis	311
7.9	Bacterial Infections	312
7.10	Acquired Immunodeficiency Syndrome (AIDS)	314
7.11	Summary	318
	Discussion Questions	320
	Problems	320
	References	321

8	Metal Ion Imbalance in the Body	329
8.1	Introduction	329
8.2	Alzheimer's Disease	329
8.2.1	The Amyloid Cascade Hypothesis	329
8.2.2	The Metal Ion Hypothesis	330
8.2.3	The Oxidative Stress Hypothesis	332
8.2.4	Metal-Chelating Agents for Treating Alzheimer's Disease	334
8.2.4.1	Clioquinol	335
8.2.4.2	Deferiprone	336
8.3	Lithium and the Brain	337
8.4	Wilson's Disease: Copper Overload	338
8.5	Menkes Disease: Copper Deficiency	340
8.6	Beta-Thalassemia: Iron Overload	342
8.6.1	Desferrioxamine B	342
8.6.2	Deferiprone	343
8.6.3	Deferasirox	343
8.7	Iron-Deficiency Anemia	344
8.8	Calcium Imbalance	344
8.9	Chelation Therapy	346
8.10	Summary	348
	Discussion Questions	349
	Problems	350
	References	351
	Further Reading	356
9	Metal Complexes for Detecting Disease	357
9.1	Introduction	357
9.2	Technetium in Diagnostic Nuclear Medicine	358
9.2.1	Clinically Used ^{99m}Tc Imaging Agents	361
9.2.2	Technetium Drugs for Selective Targeting	366
9.2.3	Innovations in Synthesis: The $[\text{Tc}(\text{CO})_3]^+$ Core	368
9.3	Metal Compounds as Contrast Agents for MRI	371
9.3.1	Clinically Used MRI Contrast Agents	376
9.3.1.1	Magnevist	377
9.3.1.2	Dotarem	378
9.3.1.3	Ablavar	378
9.3.1.4	Teslascan	380
9.3.2	Contrast Agents in Development	381
9.4	Radiotherapy	382
9.5	Summary	386
	Discussion Questions	387
	Problems	387
	References	389
	Further Reading	393
10	Nanomedicine	395
10.1	Introduction	395
10.2	Circulation, Uptake, and Elimination of Nanoparticles	396

10.2.1	The Mononuclear Phagocyte System	396
10.2.2	Enhanced Permeation and Retention (EPR) Effect	399
10.2.3	Cell-Targeting Groups	400
10.2.4	Uptake of NPs by Cells	401
10.2.4.1	Endocytosis	401
10.2.4.2	Silver Nanoparticles	401
10.2.4.3	Gold Nanoparticles	401
10.2.4.4	Carbon Nanotubes	403
10.2.4.5	Superparamagnetic Iron Oxide Nanoparticles	404
10.2.4.6	Mesoporous Nanoparticles	404
10.2.4.7	Quantum Dots	404
10.2.4.8	Metal Organic Frameworks	406
10.2.5	Biodistribution of Nanoparticles in the Body	406
10.3	Nanoscience for Treating Cancer	407
10.3.1	Gold Nanoparticles	407
10.3.2	Mesoporous Silica Nanoparticles (MSNPs)	414
10.3.3	Nano Metal–Organic Frameworks (NMOFs)	417
10.4	Nanoparticles for Detecting Disease	419
10.4.1	Magnetic Resonance Imaging (MRI)	419
10.4.2	Fluorescence Spectroscopy (FL)	421
10.5	Theranostic Nanoparticles	426
10.6	Cytotoxicity of Nanoparticles	428
10.7	Summary	429
	Discussion Questions	431
	Problems	432
	References	433
Index	441